Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 15 of 15
Full-Text Articles in Medicine and Health Sciences
Clinical And Therapeutic Sciences Iv Php 428, Joanna Burkhardt
Clinical And Therapeutic Sciences Iv Php 428, Joanna Burkhardt
Library Impact Statements
No abstract provided.
Clinical And Therapeutic Sciences Ii Php 328, Joanna Burkhardt
Clinical And Therapeutic Sciences Ii Php 328, Joanna Burkhardt
Library Impact Statements
No abstract provided.
Clinical And Therapeutic Sciences Iii Php 427, Joanna Burkhardt
Clinical And Therapeutic Sciences Iii Php 427, Joanna Burkhardt
Library Impact Statements
No abstract provided.
Clinical And Therapeutic Sciences V Php 527, Joanna Burkhardt
Clinical And Therapeutic Sciences V Php 527, Joanna Burkhardt
Library Impact Statements
No abstract provided.
Clinical And Therapeutic Sciences I Php 327, Joanna Burkhardt
Clinical And Therapeutic Sciences I Php 327, Joanna Burkhardt
Library Impact Statements
No abstract provided.
Foundational Pharmaceutical Sciences I Bps 337, Joanna Burkhardt
Foundational Pharmaceutical Sciences I Bps 337, Joanna Burkhardt
Library Impact Statements
No abstract provided.
Treatment Patterns And Economic Burden Of Sickle-Cell Disease Patients Prescribed Hydroxyurea: A Retrospective Claims-Based Study, Nirmish Shah, Menaka Bhor, Lin Xie, Rashid Halloway, Steve Arcona, Jincy Paulose, Huseyin Yuce
Treatment Patterns And Economic Burden Of Sickle-Cell Disease Patients Prescribed Hydroxyurea: A Retrospective Claims-Based Study, Nirmish Shah, Menaka Bhor, Lin Xie, Rashid Halloway, Steve Arcona, Jincy Paulose, Huseyin Yuce
Publications and Research
Background: This study aimed to evaluate sickle-cell disease (SCD) treatment patterns and economic burden among patients prescribed hydroxyurea (HU) in the US, through claims data.
Methods: SCD patients with pharmacy claims for HU were selected from the Medicaid Analytic Extracts (MAX) from January 1, 2009 - December 31, 2013. The first HU prescription during the identification period was defined as the index date and patients were required to have had continuous medical and pharmacy benefits for ≥6 months baseline and 12 months follow-up periods. Patient demographics, clinical characteristics, treatment patterns, health care utilization, and costs were examined, and variables were …
Pharmaceutical Science Internship/Field Experience Bps 460x, Joanna Burkhardt
Pharmaceutical Science Internship/Field Experience Bps 460x, Joanna Burkhardt
Library Impact Statements
No abstract provided.
Immunology And Immunotherapeutics Php/Bps 415, Joanna Burkhardt
Immunology And Immunotherapeutics Php/Bps 415, Joanna Burkhardt
Library Impact Statements
No abstract provided.
Pharmacy Law And Social Administrative Services Iv Php 408, Joanna Burkhardt
Pharmacy Law And Social Administrative Services Iv Php 408, Joanna Burkhardt
Library Impact Statements
No abstract provided.
Pharmacy Law And Social Administrative Services Iii Php 407, Joanna Burkhardt
Pharmacy Law And Social Administrative Services Iii Php 407, Joanna Burkhardt
Library Impact Statements
No abstract provided.
Dosage Forms Bps 320, Joanna Burkhardt
Dosage Forms Bps 320, Joanna Burkhardt
Library Impact Statements
No abstract provided.
Contemporary Issues In Health Sciences Chs 605, Joanna Burkhardt
Contemporary Issues In Health Sciences Chs 605, Joanna Burkhardt
Library Impact Statements
No abstract provided.
Self-Care Therapeutics And Non-Prescription Drugs I Php 319, Joanna Burkhardt
Self-Care Therapeutics And Non-Prescription Drugs I Php 319, Joanna Burkhardt
Library Impact Statements
No abstract provided.
Biopharmaceutics And Physical Pharmacy Bps 307, Joanna Burkhardt
Biopharmaceutics And Physical Pharmacy Bps 307, Joanna Burkhardt
Library Impact Statements
No abstract provided.